Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 3/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21026154 | 0.82 | LMNA (0.63) | SIGMAR1ALDH1A1LMNATSHR | |
| SCHEMBL17678058 | 0.82 | P2RX7 (0.46) | SIGMAR1ALDH1A1P2RX7OPRK1LMNA | |
| SCHEMBL21026262 | 0.76 | KDM4E (0.50) | KDM4ERECQLSIGMAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL18731438 | 0.76 | LMNA (0.53) | KDM4EHRH3P2RX7OPRK1LMNA | |
| SCHEMBL17678282 | 0.75 | LMNA (0.40) | HRH3P2RX7OPRK1LMNAMC4R | |
| SCHEMBL18732121 | 0.74 | LMNA (0.51) | SIGMAR1P2RX7LMNA | |
| SCHEMBL18731439 | 0.73 | LMNA (0.61) | KDM4EALDH1A1SMN1; SMN2P2RX7LMNA | |
| SCHEMBL21026148 | 0.72 | LMNA (0.49) | KDM4ESIGMAR1ALDH1A1SMN1; SMN2P2RX7 | |
| SCHEMBL8279311 | 0.72 | ESRRA (0.52) | KDM4EALDH1A1LMNA | |
| SCHEMBL21025767 | 0.72 | LMNA (0.58) | ALDH1A1P2RX7LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | HPSE, GAA, MAN2B1 | KDM4E 3788/4885RECQL 1542/4885SIGMAR1 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.